istribution, production and/or launch of new finished products; changes in
the regulatory process; changes in market trends; and, a number of other
factors and risks described from time to time in the Company's filings with
the Securities & Exchange Commission.
CARRINGTON LABORATORIES, INC.
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except per share amounts)
Three Months Ended Nine Months Ended
September 30, September 30,
2007 2006 2007 2006
Revenue:
Medical Services $1,842 $2,161 $5,991 $6,383
Royalty income 104 104 312 312
Medical Services, total 1,946 2,265 6,303 6,695
Consumer Services 3,767 3,580 9,128 12,465
Grant income, DelSite 776 811 1,399 1,506
Total revenues 6,489 6,656 16,830 20,666
Cost and expenses:
Cost of product sales 4,428 4,615 12,418 15,257
Selling, general and
administrative 1,935 1,884 5,724 5,652
Research and development 151 171 459 536
Research and development -
DelSite 1,300 1,503 3,575 3,985
Other income (8) (19) (25) (36)
Interest expense, net 932 266 1,771 723
Net income (loss) before
income taxes (2,249) (1,764) (7,092) (5,451)
Provision for income taxes - - - -
Net income (loss) $(2,249) $(1,764) $(7,092) $(5,451
'/>"/>
SOURCE Carrington Laboratories, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related biology technology :1.
Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets2.
Carrington Reports Second Quarter 2007 Results3.
Carrington Completes $8 Million Financing4.
Carrington Reports on ISO 9001:2000 Inspection at Sabila Industrial in Costa Rica5.
Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines6.
Carrington and DaySpring Pharma Extend and Formalize Agreement for Distribution of Diabetic and Radiation Products Into Physician Market7.
Carrington Laboratories Common Stock Now Trading on the OTC Bulletin Board: CARN.OB8.
Carrington Reports on ISO 9001:2000 Inspection9.
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound10.
QMed, Inc. Reports July Medicare SNP Enrollments11.
Phlo Affiliate Reports Expanded Coverage to Oregon Border